Clinical Trial Update: Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VEGF-B blockade with monoclonal antibody CSL346 in diabetic kidney disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease

Drugs mentioned

• CSL346

Snippet

Sponsor: CSL Behring | Conditions: Diabetic Kidney Disease (DKD) | Phase 2 | Status: COMPLETED | Results posted: 2023-12-06